long intergenic non-protein coding RNA 2150Genealiases: []
Q-omics provides the consensus-scored LINC02150 profile across patient tissues and cancer cell-line models. LINC02150 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LINC02150 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, LINC02150 RNA expression shows 6,653 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, KIRC, and STAD as cancer lineages where LINC02150 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02150 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02150 survival associations across molecular data types. LINC02150 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02150 RNA expression–survival associations across cancer types. High LINC02150 expression shows unfavorable associations in KICH, DLBC and BRCA, but favorable associations in UCS, PAAD and THYM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for LINC02150 RNA expression.
This table summarizes LINC02150 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02150. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02150 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, UCEC, THCA and HNSC. The KIRC box plot shows higher LINC02150 RNA expression in tumor versus normal tissue (log2 FC = +0.028, t-test p = .005).
This table shows molecular features associated with LINC02150 in patient tissues and cancer cell lines. In patient samples, LINC02150 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
